Lifecycle mgmt in the pharmaceutical industry

Description
This is a presentation explains about what is lifecycle management, why LCM has become so important these days, strategies that are currently being used by pharmaceutical companies and effective LCM strategies.

Presentation on Lifecycle management in the pharmaceutical industry: The Unexploited Potential

What is LCM?
?

Number of strategies used by business management as a product moves through its life-cycle.

?

The life cycle signifies the period from the product’s first launch into the
market till its final withdrawal.

?

The success of the product is reflected in terms of sales and revenue generated by it over the various stages of life cycle.

?

Effective control and prevention of decline of product as well as continuous profit generation can be achieved through effective LCM

Why LCM has become important these days?
Reevaluate diversification strategies

How to best utilize the opportunity of patent expirations

Patent cliff

Evaluate their standing in generic drugs

Change in approach

Strategies currently being used by pharmaceutical companies

? ? ?

Reformulations, new combinations of drugs and expanded indication ranges,

Use of alliances, licensing, mergers and acquisitions.

Effective LCM strategies
New indications

Store brand generics

Formulation variants

Rx to OTC switch

Extended/ controlled release variants

Illustrations
?

A regulatory strategy of switching the dosage form (capsules to tablets) to halt the market erosion. - Medicis switched patients on Dynacin capsules to Dynacin tablets long after generic market incursion occurred.

?

A change in the dosage strength (0.75% to 1%) and patent strategy to retain patients before the loss of market exclusivity. - Galderma switched patients from old 0.75% MetroGel strength to new 1% MetroGel strength.

?

An Rx-to-Rx and Rx-to-OTC switch and patent strategy for increasing

the life of drug.
- AstraZeneca switches patients on Rx Prilosec to Rx Nexium and switches Rx Prilosec to OTC Prilosec before loss of exclusivity.

Continued
?

A new launch and patent strategy of line extensions to halt erosion of market share of an ageing pharmaceutical asset.

- Bristol-Myers Squibb switches patients on Glucophage to Glucophage XR
and Glucovance.
?

A redevelopment and patent strategy to reintroduce a very old genericised drug. - Niacin (nicotinic acid) is reintroduced as Niaspan to treat abnormal cholesterol levels once a day at night.

Conclusion
?

Innovative companies can successfully breathe new life into their ageing pharmaceutical assets.

?

Appropriate strategic planning and life cycle management should be
implemented properly.

?

Also generic companies should plan on how to best utilise the new opportunities resulting from patent expirations as well as think about their investment in new drug development or successful application of LCM strategy to their generic drug so as to preserve their revenues and profits.

THANK YOU



doc_177593265.pptx
 

Attachments

Back
Top